Pharmasset Moving Back Up Again

Pharmasset, Inc. VRUS shares are moving back towards session highs, after a steep sell off following positive news this morning. Shares started the session up nearly 25% on news that the company's hepatitis C drug was essentially effective, as the Princeton, N.J.-based company said it was expanding its trial. Shares touched a high of $135.92 after opening at $120.87. At last check, shares were up $11.37 to $119.67, a gain of 10.50% on more than 3 million shares. Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing novel drugs to treat viral infections.